As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.
13 Analysts have issued a Clene Inc forecast:
13 Analysts have issued a Clene Inc forecast:
| Jun '25 | 
    +/-
   
    %
   | ||
| Revenue | 0.29 0.29 | 
      
        
        34%
      
      
        
        34%
      
 | |
| Gross Profit | 0.23 0.23 | 
      
        
        36%
      
      
        
        36%
      
 | |
| EBITDA | -25 -25 | 
      
        
        27%
      
      
        
        27%
      
 | |
| EBIT (Operating Income) EBIT | -27 -27 | 
      
        
        26%
      
      
        
        26%
      
 | |
| Net Profit | -30 -30 | 
      
        
        2%
      
      
        
        2%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
| Head office | United States | 
| CEO | Robert Etherington | 
| Employees | 76 | 
| Founded | 2013 | 
| Website | clene.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


